KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VivoSim Labs (VIVS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for VivoSim Labs (VIVS) over the last 16 years, with Q4 2025 value amounting to $4.3 million.

  • VivoSim Labs' Cash & Equivalents rose 27037.04% to $4.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.3 million, marking a year-over-year increase of 27037.04%. This contributed to the annual value of $11.3 million for FY2025, which is 28993.45% up from last year.
  • Latest data reveals that VivoSim Labs reported Cash & Equivalents of $4.3 million as of Q4 2025, which was up 27037.04% from $6.7 million recorded in Q3 2025.
  • In the past 5 years, VivoSim Labs' Cash & Equivalents registered a high of $37.4 million during Q1 2021, and its lowest value of $1.2 million during Q4 2024.
  • In the last 5 years, VivoSim Labs' Cash & Equivalents had a median value of $11.0 million in 2023 and averaged $14.9 million.
  • As far as peak fluctuations go, VivoSim Labs' Cash & Equivalents plummeted by 8104.05% in 2024, and later surged by 28993.45% in 2025.
  • VivoSim Labs' Cash & Equivalents (Quarter) stood at $30.3 million in 2021, then plummeted by 33.28% to $20.2 million in 2022, then tumbled by 73.78% to $5.3 million in 2023, then tumbled by 78.07% to $1.2 million in 2024, then surged by 270.37% to $4.3 million in 2025.
  • Its Cash & Equivalents was $4.3 million in Q4 2025, compared to $6.7 million in Q3 2025 and $9.1 million in Q2 2025.